Inquiry Basket
Loading ......
Filter By Product Search for
Streptomycin
Streptomycin Full Name
Streptomycin
Streptomycin Introduction
Streptomycin remains a cornerstone in antibacterial therapy, yet many researchers and clinicians still face a persistent challenge: how can a drug that so effectively inhibits bacterial growth also lead to resistance and host toxicity? At its core, streptomycin targets the bacterial ribosome, specifically binding to the 30S small subunit and disrupting the fidelity of protein synthesis. By interfering with the decoding center, it induces misreading of mRNA and ultimately halts bacterial protein production, leading to cell death. This mechanism underpins its strong activity against Gram-negative bacteria and acid-fast organisms, including Mycobacterium tuberculosis. However, despite its historical importance, optimizing its efficacy while minimizing unintended effects remains a key concern in both clinical and research settings.
Recent structural biology advances have significantly deepened our understanding of streptomycin's target interactions, addressing a major knowledge gap for scientists working on antibiotic specificity and safety. High-resolution studies of the human mitochondrial small ribosomal subunit have revealed that streptomycin can bind not only to bacterial ribosomes but also to mitoribosomes, explaining its well-documented ototoxicity. Notably, the identification of iron–sulfur (Fe–S) clusters and associated physiological molecules within the binding interface provides new insight into how this antibiotic stabilizes its interaction in a cellular context. Complementary computational analyses further suggest that water molecules, metal ions, and even the hydrated hemiacetal form of streptomycin contribute to its binding conformation. These findings are particularly valuable for drug developers seeking to design next-generation aminoglycosides with improved selectivity and reduced off-target effects.
Another critical pain point in streptomycin research is the growing prevalence of antimicrobial resistance, especially in tuberculosis treatment. Emerging evidence highlights that mutations in bacterial targets, such as the GidB methyltransferase in Mycobacterium tuberculosis, can significantly reduce streptomycin binding affinity. These structural alterations impair the interaction between the drug and its ribosomal target, leading to diminished therapeutic efficacy. Computational models have demonstrated that such mutations disrupt not only direct binding but also broader allosteric regulatory networks within the ribosome, emphasizing the complexity of resistance mechanisms. Together, these insights underscore the urgent need for continuous surveillance of resistance-associated mutations and the rational design of modified antibiotics to overcome them, ensuring streptomycin remains a viable tool in the fight against infectious diseases.
Alternate Names for Streptomycin
Streptomycin
Loading ......
